IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GEROSA, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.722
AS - Asia 9.870
EU - Europa 9.709
SA - Sud America 1.452
AF - Africa 259
OC - Oceania 152
Continente sconosciuto - Info sul continente non disponibili 10
Totale 32.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.717
CN - Cina 3.273
SG - Singapore 2.308
GB - Regno Unito 2.053
IT - Italia 1.804
DE - Germania 1.295
HK - Hong Kong 838
ES - Italia 790
VN - Vietnam 745
BR - Brasile 708
FR - Francia 687
RU - Federazione Russa 663
JP - Giappone 557
SE - Svezia 542
BD - Bangladesh 485
CA - Canada 472
MX - Messico 432
IN - India 420
NL - Olanda 377
CO - Colombia 268
IE - Irlanda 218
AR - Argentina 201
KR - Corea 199
FI - Finlandia 163
ID - Indonesia 162
TR - Turchia 162
PL - Polonia 142
AU - Australia 137
UA - Ucraina 136
DK - Danimarca 129
GR - Grecia 117
CH - Svizzera 110
BE - Belgio 103
TW - Taiwan 95
SA - Arabia Saudita 91
TH - Thailandia 90
PE - Perù 70
IL - Israele 64
EC - Ecuador 62
PT - Portogallo 61
EG - Egitto 58
JO - Giordania 57
RO - Romania 55
AT - Austria 53
CI - Costa d'Avorio 49
CL - Cile 47
PK - Pakistan 46
ZA - Sudafrica 44
PH - Filippine 43
IR - Iran 40
EU - Europa 39
VE - Venezuela 39
UY - Uruguay 34
NO - Norvegia 32
MY - Malesia 31
IQ - Iraq 28
CZ - Repubblica Ceca 23
KE - Kenya 23
RS - Serbia 23
UZ - Uzbekistan 21
MA - Marocco 19
AE - Emirati Arabi Uniti 17
BG - Bulgaria 16
HR - Croazia 16
HU - Ungheria 16
TN - Tunisia 16
BA - Bosnia-Erzegovina 14
CR - Costa Rica 14
LT - Lituania 14
NZ - Nuova Zelanda 13
NI - Nicaragua 12
PY - Paraguay 12
DZ - Algeria 11
GT - Guatemala 11
KZ - Kazakistan 11
LV - Lettonia 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
SI - Slovenia 10
BO - Bolivia 9
LB - Libano 9
PR - Porto Rico 9
AL - Albania 8
ET - Etiopia 8
HN - Honduras 8
PA - Panama 7
QA - Qatar 7
SV - El Salvador 7
BY - Bielorussia 6
JM - Giamaica 6
KW - Kuwait 6
NP - Nepal 6
UG - Uganda 6
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
CU - Cuba 4
CY - Cipro 4
EE - Estonia 4
GE - Georgia 4
Totale 32.116
Salva come PNG Salva come JPEG
Città #
Southend 1.446
Singapore 1.281
Ashburn 845
Dallas 746
Hong Kong 669
San Jose 537
Milan 526
Chandler 484
Beijing 469
New York 370
Council Bluffs 280
Seattle 271
Hanover 255
Redwood City 233
Santa Clara 230
Ho Chi Minh City 228
Frankfurt am Main 226
Fairfield 225
Los Angeles 224
Princeton 202
Wilmington 200
Dublin 195
Hanoi 182
Guangzhou 173
Shanghai 173
Hefei 170
Munich 167
Tokyo 166
Ann Arbor 162
Houston 146
Moscow 144
Lauterbourg 143
Nanjing 138
Woodbridge 131
Bengaluru 129
Dearborn 129
Madrid 125
Buffalo 115
Bogotá 114
Montréal 113
Cambridge 101
Chicago 100
Toronto 99
São Paulo 92
Jacksonville 89
Jakarta 87
Mcallen 87
Des Moines 84
Hangzhou 81
Mexico City 81
Helsinki 78
Rome 76
Seoul 76
The Dalles 76
Warsaw 75
Berlin 71
Barcelona 70
Jinan 69
Changsha 68
Phoenix 67
Columbus 65
Paris 57
London 56
Granada 54
Brooklyn 53
Istanbul 52
Taipei 51
Athens 50
Medellín 50
Abidjan 49
Chengdu 49
Mountain View 49
Lima 48
Boardman 47
Tianjin 47
Amman 45
Buenos Aires 45
Shenzhen 45
Córdoba 44
Da Nang 44
Zhengzhou 44
Boston 43
Washington 43
Brussels 42
Fuzhou 41
Amsterdam 40
Shenyang 40
Redmond 39
Nuremberg 38
Wuhan 38
Ottawa 37
Denver 36
Montreal 36
Cangzhou 35
Chongqing 35
Osaka 35
Riyadh 35
Sunnyvale 35
Naples 34
Jeddah 32
Totale 16.147
Salva come PNG Salva come JPEG
Nome #
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 5.232
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases 2.272
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study 1.413
IL-10 producing regulatory and helper T-cells in systemic lupus erythematosus 910
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications 534
Complement activation in anti-phospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 494
Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome 464
P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus 415
Are patients with systemic lupus erythematosus at increased risk for COVID-19? 364
Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis 330
Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome 324
COVID-19 in systemic lupus erythematosus : data from a survey on 417 patients 319
Pidotimod : a reappraisal 299
Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome 290
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 288
Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases 288
Evidence for a pathogenic role of extrafollicular, IL-10–producing CCR6+B helper T cells in systemic lupus erythematosus 287
Circulating stem cell factor in patients with chronic idiopathic urticaria 272
The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies 269
Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals 253
Disease knowledge index and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases 245
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers 243
Fluctuation of Anti–Domain 1 and Anti–β2‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies 233
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants 232
Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus 231
Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs : an Italian multicentre study 230
Production of anti-{PF}4 antibodies in antiphospholipid antibody-positive patients is not affected by {COVID}-19 vaccination 223
Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study 218
Patients with antiphospholipid syndrome display endothelial perturbation 214
Cardiac involvement in systemic autoimmune diseases 213
Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort 212
Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss 210
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide : a phase II pilot study 206
Antiphospholipid antibodies and ex-vivo endothelial perturbation 203
Up-date on the antiphospholipid syndrome 201
Endothelium as a target for antiphospholipid antibodies 198
Systemic Lupus erythematosus complicated by thrombotic thrombocytopenic purpura 195
Anti-DNA antibodies : a diagnostic and prognostic tool for systemic lupus erythematosus? 193
The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies 191
Rheumatoid arthritis : a female challenge 190
Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study 187
IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases 187
Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases 184
Statins and autoimmune diseases 183
Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block : an Italian multicentre cross-sectional study on behalf of the "Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group" 182
Obstetric antiphospholipid syndrome: Lobsters only? or should we also look for selected red herrings? 182
Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein i domain 1 and domain 4/5 : ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome 181
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies 177
Antibodies Against Domain 1 and Domain 4/5 of β2 Glycoprotein I : Clinical Relevance in Obstetric Anti-Phospholipid Syndrome 175
Defective regulation by ATP-GATED ionotropic P2X7 receptor drives T follicular helper cell expansion in systemic lupus erythematosus 174
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies 174
Counseling on family planning and contraception in patients with rheumatic diseases : Analysis of 324 patient-reported questionnaires from a multicenter Italian study 172
Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination 171
Antiphospholipid syndrome and systemic lupus erythematosus patients: what's new about cognitive involvement? 171
Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus 170
Anti-NR2 antibodies and primary antiphospholipid syndrome : a preliminary study 170
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 166
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 166
Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity 164
Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases 163
Diversity and somatic hypermutation of the Ig VHDJH, V kappa J kappa, and V lambda J lambda gene segments in lymphoma B cells : relevance to the origin of the neoplastic B cell clone 163
Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies 163
Challenges and treatment options for rheumatoid arthritis during pregnancy 160
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting : results of a large, multicentric, nationwide study 158
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 157
Long Term Outcomes of Anti-COVID-19 Vaccines in Patients with Systemic Lupus Erythematosus: A Multicentre Study 157
Lung Disease in Antiphospholipid Syndrome 156
Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome 153
Management of the controversial aspects of the antiphospholipid syndrome pregnancies : a guide for clinicians and researchers 152
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors 152
Thrombotic vs obstetric antiphospholipid syndrome: a role for constitutive endothelial dysfunction 152
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases) 150
Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block : lesson from twins and triplets discordant for the disease 150
Pregnancy outcomes in women exposed to biologic treatment and affected by chronic arthritis 149
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for disorders of the immune system 144
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases 143
Chronic urticaria : new immunologic aspects 142
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study 138
Differential impairment of serum cholesterol efflux capacity in patients with rheumatoid arthritis and systemic lupus erythematosus 135
Succesfull sequential therapy with rituximab and belimumab in three patients with active systemic lupus erythematosus 134
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up 133
Update on pregnancy in autoimmune diseases 132
The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry 131
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers 131
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study 130
Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction 130
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases 129
Antiphospholipid syndrome and systemic lupus erythematosus patients: what's new about cognitive involvement? 127
Anti-SSA/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases 126
Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series 125
Investigating the role of Endothelial Dysfunction in Antiphospholipid Syndrome by using Patient-Specific Endothelial Colony-Forming Cells 124
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No 124
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort 123
Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients 123
Primary anti-phospholipid syndrome : any role for serum complement levels in predicting pregnancy complications? 122
Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants 121
The use of biologics and small molecules in pregnant patients with rheumatic diseases 121
Safety considerations when prescribing immunosuppression medication to pregnant women 120
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients : Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository 119
Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients 118
Totale 28.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.061
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.061
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021660 0 0 0 0 0 0 0 0 0 0 360 300
2021/20223.276 275 258 245 292 293 187 244 250 310 299 232 391
2022/20233.365 303 291 273 259 303 397 203 262 334 212 306 222
2023/20242.978 167 250 197 256 595 195 203 204 121 180 274 336
2024/20254.935 219 459 217 448 427 286 275 470 321 476 469 868
2025/202611.166 838 620 1.316 1.077 1.228 729 1.367 611 1.168 827 1.385 0
Totale 33.376